Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IRB 2024-587 | Other Identifier | Texas Tech University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Strength and Conditioning Association | OTHER |
Not provided
Not provided
Not provided
Not provided
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
After screening and providing informed consent, participants (healthy older adults, age 60+, minimally active) will be familiarized with the procedures and undergo pre-testing. After pre-testing, participants will be assigned to supplement with resveratrol or placebo (double-blinded) daily while undergoing a strength training intervention. Strength training will be performed 3x/week for two 6-week blocks, and each visit will be supervised by a member of the study team. An additional week of testing will follow each of the two 6-week blocks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Resveratrol (RSV) group | Experimental | Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
|
| Placebo | Placebo Comparator | Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Resistance training | Behavioral | After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block. |
| Measure | Description | Time Frame |
|---|---|---|
| Circulating extracellular vesicle microRNA profile | Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced. | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Muscle torque | Participants will be instructed to try and straighten their leg, against resistance, as forcefully as possible and maximal torque of the quadriceps assessed using a dynamometer. | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Muscle fatigability | Participants will perform 32 repetitions of knee extensions on a dynamometer and the change in torque from the beginning to the end will be used to indicate fatigability. | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Muscle strength | Participants will perform submaximal testing to assess strength on key exercises included in the strength training protocol. | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Appendicular skeletal muscle mass index | Assessed using dual-energy x-ray absorptiometry (DEXA) | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Waist-to-hip ratio | Waist and hip circumferences measured using measuring tape | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Vascular function | Flow-mediated dilation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Danielle E Levitt, PhD | Contact | 806-834-1830 | danielle.levitt@ttu.edu | |
| Jacob A Mota, PhD | Contact | 806-834-8772 | jacob.mota@ttu.edu |
| Name | Affiliation | Role |
|---|---|---|
| Danielle E Levitt, PhD | Texas Tech University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Kinesiology & Sport Management, Texas Tech University | Recruiting | Lubbock | Texas | 79409 | United States |
De-identified data from human participants (other than large-scale data) will be deposited into the TTU Dataverse with restricted access - by request only. Data will be linked only with a unique code.
MicroRNA sequencing data will be deposited to the Gene Expression Omnibus (GEO).
The following will be submitted to accompany data:
Dr. Danielle Levitt (PI) will deposit data into the appropriate repositories. Data upload will occur when publications associated with each data set are submitted and made public (where applicable) upon acceptance.
Human participants data (except large-scale data sets)- reasonable requests must be submitted to the TTU Dataverse.
MicroRNA sequencing data will be available in large-scale output format with no identifiable information (unique code).
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D055070 | Resistance Training |
| D000077185 | Resveratrol |
| ID | Term |
|---|---|
| D005081 | Exercise Therapy |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
Not provided
Not provided
After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.
Not provided
Not provided
Not provided
|
|
| Resveratrol 500 mg oral once daily. | Dietary Supplement | Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
|
| Placebo | Dietary Supplement | Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training [supervised, full-body, 3 days/week] + one testing week [3 days] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored. |
|
| During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Cognitive function | Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Grip strength | Handgrip dynamometry | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Lower body strength/endurance | Chair stand test (30 seconds) | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| Gait speed | 4-m walk test | During pre-, mid-, and post-testing (each separated by about 6 weeks) |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D005791 |
| Patient Care |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
| D000081225 | Stilbestrols |
| D013267 | Stilbenes |
| D001597 | Benzylidene Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D059808 | Polyphenols |
| D010636 | Phenols |